

Ingrid Dieset

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/215780/publications.pdf>

Version: 2024-02-01

50
papers

1,964
citations

257450

24
h-index

265206

42
g-index

51
all docs

51
docs citations

51
times ranked

3549
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-18 signaling system links to agitation in severe mental disorders. <i>Psychoneuroendocrinology</i> , 2022, 140, 105721.	2.7	6
2	Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2021, 21, 574-585.	2.0	5
3	Lessons learned from a cross-sectional survey among patients and staff in an acute psychiatric unit during an ongoing pandemic outbreak. <i>Psychiatry Research</i> , 2021, 298, 113779.	3.3	6
4	Adiponectin Is Related to Cardiovascular Risk in Severe Mental Illness Independent of Antipsychotic Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 623192.	2.6	6
5	Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. <i>Psychological Medicine</i> , 2020, 50, 595-606.	4.5	23
6	Patient satisfaction and acute psychiatric inpatient treatment. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 577-584.	1.3	8
7	Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 642.	2.6	5
8	Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 672.	2.6	15
9	T8. ATHEROGENIC LIPID RATIOS RELATED TO MYELOPEROXIDASE AND C-REACTIVE PROTEIN LEVELS IN PSYCHOTIC DISORDERS. <i>Schizophrenia Bulletin</i> , 2019, 45, S206-S206.	4.3	3
10	Inflammatory markers are altered in severe mental disorders independent of comorbid cardiometabolic disease risk factors. <i>Psychological Medicine</i> , 2019, 49, 1749-1757.	4.5	40
11	Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 348-360.	4.5	31
12	Association between leptin levels and severity of suicidal behaviour in schizophrenia spectrum disorders. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 464-471.	4.5	15
13	Oxytocin pathway gene networks in the human brain. <i>Nature Communications</i> , 2019, 10, 668.	12.8	200
14	Response: Are thyroid abnormalities only related to antipsychotic treatment in patients with severe mental disorders?. <i>Journal of Psychiatric Research</i> , 2019, 117, 150.	3.1	0
15	Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. <i>Psychoneuroendocrinology</i> , 2019, 103, 87-95.	2.7	20
16	An association between γ -GluT and type 2 diabetes in psychotic disorders. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 37-45.	4.5	8
17	Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 795-802.	3.2	17
18	Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder. <i>Translational Psychiatry</i> , 2018, 8, 55.	4.8	94

#	ARTICLE	IF	CITATIONS
19	Identification of shared genetic variants between schizophrenia and lung cancer. <i>Scientific Reports</i> , 2018, 8, 674.	3.3	33
20	Attenuated Notch signaling in schizophrenia and bipolar disorder. <i>Scientific Reports</i> , 2018, 8, 5349.	3.3	37
21	Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics. <i>European Psychiatry</i> , 2018, 48, 71-78.	0.2	4
22	Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 82, 263-271.	4.8	77
23	Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 197, 253-260.	2.0	24
24	F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS. <i>Schizophrenia Bulletin</i> , 2018, 44, S227-S227.	4.3	0
25	Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. <i>Journal of Psychiatric Research</i> , 2018, 106, 74-81.	3.1	31
26	Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up. <i>Psychiatry Research</i> , 2018, 267, 140-147.	3.3	13
27	Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. <i>Frontiers in Psychiatry</i> , 2018, 9, 753.	2.6	58
28	A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw183.	4.3	47
29	Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 342-349.	4.1	67
30	Oxytocin system dysfunction as a common mechanism underlying metabolic syndrome and psychiatric symptoms in schizophrenia and bipolar disorders. <i>Frontiers in Neuroendocrinology</i> , 2017, 45, 1-10.	5.2	26
31	Selective serotonin reuptake inhibitors, anti-psychotics and metabolic risk factors in schizophrenia and bipolar disorder. <i>European Psychiatry</i> , 2017, 41, S752-S752.	0.2	0
32	Persistent increase in TNF and IL-1 markers in severe mental disorders suggests trait-related inflammation: a one year follow-up study. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 400-408.	4.5	23
33	Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 471-482.	2.6	18
34	Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 24.	2.2	7
35	Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span. <i>Schizophrenia Bulletin</i> , 2016, 42, 1316-1319.	4.3	69
36	Low vitamin D is associated with negative and depressive symptoms in psychotic disorders. <i>Schizophrenia Research</i> , 2016, 178, 44-49.	2.0	29

#	ARTICLE	IF	CITATIONS
37	<i>VRK2</i> gene expression in schizophrenia, bipolar disorder and healthy controls. British Journal of Psychiatry, 2016, 209, 114-120.	2.8	17
38	Association between cytokine levels, verbal memory and hippocampus volume in psychotic disorders and healthy controls. Acta Psychiatrica Scandinavica, 2016, 133, 53-62.	4.5	48
39	Relationship of suicide rates with climate and economic variables in Europe during 2000-2012. Annals of General Psychiatry, 2016, 15, 19.	2.7	48
40	Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology, 2016, 67, 189-197.	2.7	39
41	Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophrenia Research, 2015, 165, 188-194.	2.0	85
42	Serum level of venlafaxine is associated with better memory in psychotic disorders. Schizophrenia Research, 2015, 169, 386-392.	2.0	10
43	Association between altered brain morphology and elevated peripheral endothelial markers – Implications for psychotic disorders. Schizophrenia Research, 2015, 161, 222-228.	2.0	23
44	Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions. Frontiers in Psychiatry, 2014, 5, 137.	2.6	247
45	Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders. Journal of Psychiatric Research, 2014, 52, 57-62.	3.1	36
46	Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophrenia Research, 2013, 145, 36-42.	2.0	118
47	Response to Li and Su Letter. American Journal of Psychiatry, 2013, 170, 561-561.	7.2	0
48	Up-Regulation of <i>NOTCH4</i> Gene Expression in Bipolar Disorder. American Journal of Psychiatry, 2012, 169, 1292-1300.	7.2	44
49	Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophrenia Research, 2012, 140, 169-174.	2.0	38
50	Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. Journal of Psychiatric Research, 2011, 45, 1608-1616.	3.1	146